An Immunohistochemical Study for Mammalian Target of Rapamycin Signaling Pathway Including Interacting PTEN in Prostatic Acinar Adenocarcinoma and Correlation with the Patient Clinicopathological Parameters

Background: The activation of AKT-mTOR-PTEN pathway may promote prostate cancer progression and affects response to targeted therapies. full extent this remains be determined. Our aim: was assess the expression inactive mTOR, phosphor-mTOR, phosphor-AKT loss PTEN in prostatic adenocarcinomas then correlate their with clinicopathological parameters.
 Methods: study included 166 adenocarcinoma tissues using immunohistochemistry on tissue microarrays. Statistical analysis considering markers correlation clinicopathologic parameters done appropriate tests.
 Result: mean age 72.63 75.9% were clinically high risk. Gleason score 7 WHO grade group 5 commonest (31.3% 31.9% respectively). Most patient (73.1%) stage T2 or higher. Expression phospho-mTOR seen 96.1%, 93.5% 95.9% respectively. noted 55.3%. There significant correlations between pattern 4 mTOR (p value <0.001 0.004 respectively) 0.003 0.001 significantly correlated <0.001). also phospho- p 0.004.
 Conclusion: immunohistochemical phosphor-mTOR appreciated most cases, suggesting that occur early during tumorigenesis. This indicate targeting have a promising therapeutic role management adenocarcinoma.